四环生物(000518) - 2015 Q1 - 季度财报

Revenue and Profit - Revenue for Q1 2015 was CNY 46,987,464.09, a decrease of 37.14% compared to CNY 74,755,076.02 in the same period last year[8] - Net profit attributable to shareholders was CNY 10,098,042.27, down 21.31% from CNY 12,833,227.70 year-on-year[8] - Basic earnings per share decreased by 21.60% to CNY 0.0098 from CNY 0.0125 in the previous year[8] - Operating revenue decreased by 37.14% to ¥46,987,464.09, reflecting a sales decline in Beijing and Jiangsu[15] - Operating costs fell by 34.82% to ¥16,995,134.75, corresponding to the decrease in revenue[15] - Sales expenses dropped by 81.80% to ¥1,986,607.25, as advertising costs were reduced[15] Cash Flow and Assets - Net cash flow from operating activities improved significantly to CNY 740,056.43, a 225.15% increase from a negative CNY 591,346.92 in the same period last year[8] - Cash and cash equivalents increased by 94.05% to ¥67,425,552.42 due to new short-term borrowings[15] - Financing activities generated a net cash flow of ¥33,968,977.25, a significant increase due to new short-term borrowings[16] - Total assets at the end of the reporting period were CNY 848,931,843.93, reflecting a 3.77% increase from CNY 818,082,450.17 at the end of the previous year[8] - Net assets attributable to shareholders increased by 1.48% to CNY 691,165,638.75 from CNY 681,067,596.48 at the end of the previous year[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 1,029,556,222[11] - The largest shareholder, Guangzhou Shengjing Investment Co., Ltd., holds 3.89% of shares, amounting to 40,000,000 shares, with some shares pledged[11] - There were no share buyback transactions conducted by the top ten shareholders during the reporting period[12] Other Financial Activities - The company reported no significant non-recurring gains or losses during the reporting period[9] - The company has not made any new investments in intangible assets during the reporting period[15] - There are no securities investments or derivative investments reported for the period[21][20] - Accounts receivable interest rose by 818.18% to ¥2,160,277.78, attributed to interest from entrusted loans[15] Company Status - The company is currently in discussions regarding a major matter that has led to the suspension of its stock since March 6, 2015[17]